Printer Friendly

CPMP APPROVES BAXTER'S RECOMBINATE ANTIHEMOPHILIC FACTOR (RECOMBINANT) FOR THE TREATMENT OF HEMOPHILIA

 CAMBRIDGE, Mass., May 13 /PRNewswire/ -- Genetics Institute, Inc. (NASDAQ: GENIZ) announced today that the European Community's Committee for Proprietary Medicinal Products (CPMP) has recommended the approval of Baxter Healthcare Corporation (Hyland Division)'s Recombinate rAHF, antihemophilic factor (recombinant), for the treatment of hemophilia A. Genetics Institute manufactures bulk recombinant Factor VIII, the drug substance used in Recombinate rAHF, for Baxter.
 Baxter's Recombinate rAHF was the first recombinant Factor VIII product to receive approval in the United States, Canada, and Sweden. Today, it is the first such product to be recommended for approval by the CPMP. Baxter introduced Recombinate* rAHF in the United States and Canada in December of 1992.
 "Today's recommendation for approval by the CPMP sets the stage for individual country approvals of Recombinate rAHF in member countries of the EEC," said John Bacich, president of Hyland. "We are poised to make Recombinate rAHF available widely throughout Europe thereby bringing a genetically engineered product with significant benefits to European patients with hemophilia."
 "We are very pleased to see Recombinate rAHF moving toward commercialization in Europe," said Gabriel Schmergel, president and CEO of Genetics Institute. "We are proud that Genetics Institute will participate in serving the needs of hemophilia patients in the U.S. and abroad as a manufacturer of bulk recombinant Factor VIII."
 Recombinate rAHF is the result of more than a 10-year research and development collaboration between Baxter and Genetics Institute. The recombinant product differs from plasma-derived products because it is produced through genetic engineering and manufactured in tissue culture, as opposed to being extracted from human blood. Because of this technology, Recombinate rAHF eliminates the risk of transmitting human viruses such as HIV and hepatitis.
 Hemophilia A is a rare, hereditary disorder caused by the absence or marked deficiency of Factor VIII within the blood. The major problem for people with hemophilia is uncontrolled bleeding, which can lead to severe joint damage and even death. It is estimated that one out of every 6,500 European males suffers from hemophilia.
 Genetics Institute is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. The company has a diversified portfolio of licensed and proprietary pharmaceutical products at various stages of development, including treatments for anemia, hemophilia, cancer, infectious disease, bone damage, heart disease, inflammatory conditions, and immune system disorders.
 American Home Products Corporation (NYSE: AHP) holds a majority interest in Genetics Institute. AHP is a world leader in marketing and manufacturing of prescription drugs, medical supplies, diagnostics, over-the-counter medicines, and food products.
 -0- 5/13/93
 /CONTACT: Dennis Harp or Gina Price, Genetics Institute,
617-876-1170; William Mutert, Hyland Division, Baxter Healthcare


Corporation, 818-507-5424/
 (GENIZ)


CO: Genetics Institue, Inc.; Baxter Healthcare Corporation ST: Massachusetts IN: MTC SU:

DJ -- NE011 -- 8252 05/13/93 15:44 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1993
Words:466
Previous Article:ULTRA PAC, INC. BREAKS GROUND FOR NEW WAREHOUSING FACILITY
Next Article:FREMONT GROUP TO PURCHASE COLDWELL BANKER RESIDENTIAL
Topics:


Related Articles
GENETICS INSTITUTE PLEASED WITH BAXTER AND RHONE-POULENC RORER FACTOR VIII PATENT SETTLEMENT
BAXTER, RHONE-POULENC RORER RESOLVE ALL DISPUTES INVOLVING FACTOR VIII:C PATENTS; SIGN PURCHASING AGREEMENT FOR BAXTER PRODUCTS
TRANSKARYOTIC THERAPIES AND GENETICS INSTITUTE COLLABORATE ON COMMERCIALIZATION OF GENE THERAPY PRODUCT FOR HEMOPHILIA A
ARMOUR TO INTRODUCE SECOND RECOMBINANT FACTOR VIII PRODUCT WORLDWIDE
GENETICS INSTITUTE APPOINTS DIRECTOR OF SALES
Hyland Division of Baxter Takes Precautionary Action With Recombinant Factor VIII Therapy
Baxter Receives FDA Approval for Second Manufacturing Suite at Thousand Oaks.
Baxter Receives European Approval for Two Additional Manufacturing Suites At Thousand Oaks.
Data Analyses Further Support Safety and Efficacy of Baxter's ADVATE For Hemophilia A; First and Only Human- and Animal Plasma Protein- and...
U.S. FDA Approves Wyeth Manufacturing Site for Hemophilia A Treatment.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters